Can a Two-Drug combo keep aggressive lymphoma at bay?

NCT ID NCT07760610

Not yet recruiting Disease control Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial is testing whether a combination of pomalidomide (a pill) and rituximab (an infusion) can help young adults with high-risk diffuse large B-cell lymphoma (DLBCL) stay in remission after their first round of treatment. Participants, who must be under 60 and have responded at least partially to initial therapy, will receive the two drugs for up to 24 months. The main goal is to see how many people remain free of cancer progression after one year, with secondary goals including overall survival and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pomalidomide combined with rituximab
What this could lead to: If successful, this maintenance regimen could help keep high-risk DLBCL in remission longer, potentially improving survival without the need for more intensive treatment.
What could go wrong: This is a small, single-center study, so results may not apply broadly. The combination may cause side effects like low blood counts or infections, and it is not yet known if it will outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

More trials for these conditions

Other studies related to the condition(s) this trial covers.